EFFICACY OF OCTREOTIDE AS ADJUVANT THERAPY FOR RECTAL ADVANCED NEUROENDOCRINE CARCINOMA-A CASE REPORT-Takahito MINAMI 1) , Tomohiko NISHIHIRA 1) , Akihiro MIKI 1) , Takahisa SUZUKI 1) , Tsuyoshi OTANI 1) , Koji KITAMURA 1) and Tetsuro OGINO 2)
Departments of Digestive Surgery 1) and Pathology 2) , Takamatsu Red Cross Hospital A woman in her eighties presenting with anal pain was referred to our hospital. Physical examinations revealed a hard rectal tumor protruding through the anus. Abdominal CT and MRI scans showed a huge tumor from the rectum to the anus accompanying by a pelvic lymph node enlargement. Although definitive preoperative diagnosis was not obtained, poorly differentiated malignant tumor was suspected because a biopsy of the tumor showed more than 90% of Ki-67 index. An abdominoperitoneal resection was performed. On histopathological examinations, the most of the tumor cells were immunohistochemically positive for neuroendocrine markers. The tumor was diagnosed as neuroendocrine carcinoma (NEC). Because the tumor cells were strongly positive for somatostatin receptor (SSTR) type 2 (SSTR2) and she was not be a candidate for general chemotherapy, we introduced i.m. administrations of octreotide LAR (30 mg) every 4 weeks. Despite extremely high Ki-67 index, she remains relapse-free for 2 years after the surgery. We recommend an application of octreotide as an adjuvant therapy for SSTR-positive NEC, when standard chemotherapy is not feasible as in the present case. Key words：rectal neuroendocrine carcinoma，adjuvant therapy，octreotide
